Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fei-Yu Zhao

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
World Journal of Radiology|December 8, 2025
Value of radiomics models in precision diagnosis of dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinomaXu Qi, Fei-Yu Zhao
World Journal of Gastroenterology|March 17, 2025
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapyFei-Yu Zhao, Xiao-Ming Zhang, Nian-Song Qian
World Journal of Gastrointestinal Oncology|October 30, 2024
Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approachFei-Yu Zhao, Dong-Yu Wang, Nian-Song Qian
World Journal of Gastrointestinal Oncology|January 16, 2025
TRIPLET combined with microwave ablation: A novel treatment for advanced hepatocellular carcinomaFei-Yu Zhao, Guo-Wei Si, Nian-Song Qian
World Journal of Gastroenterology|January 19, 2026
The triglyceride-glucose index shows promise as a novel prognostic marker for advanced hepatocellular carcinomaTao Xu, Xu Qi, Fei-Yu Zhao, et al.
World Journal of Clinical Oncology|January 2, 2026
Immune therapy-related hyperprogressive disease: Molecular mechanisms, biomarkers, and clinical strategiesXiao-Ming Zhang, Fei-Yu Zhao, Lin-Feng Gao, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
World Journal of Radiology|December 8, 2025
Value of radiomics models in precision diagnosis of dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinomaXu Qi, Fei-Yu Zhao
World Journal of Gastroenterology|March 17, 2025
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapyFei-Yu Zhao, Xiao-Ming Zhang, Nian-Song Qian
World Journal of Gastrointestinal Oncology|October 30, 2024
Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approachFei-Yu Zhao, Dong-Yu Wang, Nian-Song Qian
World Journal of Gastrointestinal Oncology|January 16, 2025
TRIPLET combined with microwave ablation: A novel treatment for advanced hepatocellular carcinomaFei-Yu Zhao, Guo-Wei Si, Nian-Song Qian
World Journal of Gastroenterology|January 19, 2026
The triglyceride-glucose index shows promise as a novel prognostic marker for advanced hepatocellular carcinomaTao Xu, Xu Qi, Fei-Yu Zhao, et al.
World Journal of Clinical Oncology|January 2, 2026
Immune therapy-related hyperprogressive disease: Molecular mechanisms, biomarkers, and clinical strategiesXiao-Ming Zhang, Fei-Yu Zhao, Lin-Feng Gao, et al.
Pageof 1